Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

cimetidine

CIMETIDINE

cimetidine (CIMETIDINE) is a histamine h2 receptor antagonist. Associated with BICYCLE THERAPEUTICS. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 5
News articles 0
Drug details — cimetidine
US status
approved
Class
—
Route
ORAL
Patents
20
Programs
5
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

cimetidine (CIMETIDINE) is a histamine h2 receptor antagonist. Associated with BICYCLE THERAPEUTICS. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN cimetidine
Brand CIMETIDINE
Mechanism Histamine H2 receptor antagonist
Target Histamine H2 receptor
Route ORAL
Formulation SUSPENSION
Originator BICYCLE THERAPEUTICS

Mechanism of action

Histamine H2 receptor antagonist

Primary target: Histamine H2 receptor

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. MK-2870-033 Phase 3 · MSD Merck Sharp · pMMR endometrial carcinoma
  2. KL264-01 Phase 2 · Anaxis Pharma · Metastatic or locally advanced unresectable solid tumors pro
  3. SKB264-II-04 Phase 2 · Anaxis Pharma · Advanced or Metastatic Non-small Cell Lung Cancer
  4. cimetidine (or acyclovir) Phase 1 · BRIGHT MINDS BIOSCIENCES · Healthy
  5. Drug: cimetidine Approved · BRIGHT MINDS BIOSCIENCES · Healthy

Related & competitor drugs

Browse all drugs
  1. cimetidine hydrochloride Histamine H2 receptor antagonist
  2. famotidine Histamine H2 receptor antagonist
  3. nizatidine Histamine H2 receptor antagonist
  4. ranitidine hydrochloride Histamine H2 receptor antagonist
  5. betazole hydrochloride Histamine H2 receptor agonist
  6. methantheline bromide Histamine H2 receptor antagonist

Related patents

Browse patents BICYCLE THERAPEUTICS patent hub

  1. US 12377155

    Bicyclic peptide ligands specific for PSMA

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12378288

    Multimeric bicyclic peptide ligands

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12350343

    Bicyclic peptide ligands specific for MT1-MMP

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12318454

    Bicyclic peptide ligands specific for MT1-MMP

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12150998

    Bicyclic peptide ligands specific for P-selectin

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12049520

    Bicyclic peptide ligands specific for CD137

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11970553

    Heterotandem bicyclic peptide complex

    Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11912792

    Bicyclic peptide ligands specific for nectin-4

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11912794

    Modulation of structured polypeptide specificity

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11904020

    Bicyclic peptide ligands specific for TREM2

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11866518

    Bicyclic peptide ligands specific for TSLP

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11814447

    Peptide ligands for binding to EphA2

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11753444

    Modulation of structured polypeptide specificity

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11746126

    Bicyclic peptide ligands with detectable moieties and uses thereof

    Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11696956

    Bicyclic peptide ligands specific for EphA2

    Expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11672868

    Bicyclic peptide ligands specific for MT1-MMP

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11623012

    Bicyclic peptide ligands specific for EphA2

    Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11613560

    Bicyclic peptide ligands specific for OX40

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11542304

    Multimeric bicyclic peptide ligands

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11484602

    Bicyclic peptide ligands specific for EphA2

    Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is cimetidine?

cimetidine (CIMETIDINE) is a histamine h2 receptor antagonist. Associated with BICYCLE THERAPEUTICS. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for cimetidine?

CIMETIDINE is a marketed brand name for cimetidine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of cimetidine?

cimetidine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.